Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin

被引:46
作者
Bettink-Remeijer, M. Wefers [1 ]
Brouwers, K. [2 ]
van Langenhove, L. [2 ]
De Waard, P. W. T.
Missotten, T. O.
Ciriano, J. P. Martinez
Van Aken, E. [3 ]
机构
[1] Rotterdam Eye Hosp, Oogziekenhuis Rotterdam, Dept Ophthalmol, NL-3011 BH Rotterdam, Netherlands
[2] Univ Hosp Brussels, Dept Ophthalmol, Brussels, Belgium
[3] Ghent Univ Hosp, Serv Med Retina & Vitreoretinal Surg, Dept Ophthalmol, B-9000 Ghent, Belgium
关键词
moxifloxacin; uveitis; iris transillumination; sphincter paralysis; adverse effect; PHARMACOKINETICS; MELANIN;
D O I
10.1038/eye.2009.234
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective To report a newly recognized adverse effect of oral moxifloxacin. Design Observational case reports. Participants Five patients who used oral moxifloxacin therapy. Main outcome measures In five patients, a uveitis-like episode followed oral moxifloxacin therapy, afterwards they experienced photophobia. At slitlamp investigation, the patients showed almost complete iris transillumination, not restricted to one sector, and persistent mydriasis of the pupil, with no reaction to light and no near reflex. Follow-up of 3 years in one of the patients showed no change of symptoms. Only in one patient, with a history of anterior uveitis, an anterior chamber tap was positive for herpes simplex genome. Only after the use of moxifloxacin did she experience continuous photophobia. Conclusions Iris transillumination and sphincter paralysis is a newly recognized adverse effect of oral moxifloxacin therapy. Eye (2009) 23, 2260-2262; doi:10.1038/eye.2009.234; published online 23 October 2009
引用
收藏
页码:2260 / 2262
页数:3
相关论文
共 6 条
[1]  
Bringas Calvo R., 2004, Arch Soc Esp Oftalmol, V79, P357
[2]   Retinal pigment epithelium melanin and ocular toxicity [J].
Dayhaw-Barker, P .
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2002, 21 (06) :451-454
[3]   Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis [J].
De Groot-Mijnes, JDF ;
Rothova, A ;
Van Loon, AM ;
Schuller, M ;
Loon, NHT ;
De Boer, JH ;
Schuurman, R ;
Weersink, AJL .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 141 (02) :313-318
[4]   Melanocyte melanin augments sparfloxacin-induced phototoxicity [J].
Hamanaka, H ;
Mizutani, H ;
Asahig, K ;
Shimizu, M .
JOURNAL OF DERMATOLOGICAL SCIENCE, 1999, 21 (01) :27-33
[5]   Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous [J].
Hariprasad, SM ;
Blinder, KJ ;
Shah, GK ;
Apte, RS ;
Rosenblatt, B ;
Holekamp, NM ;
Thomas, MA ;
Mieler, WF ;
Chi, JD ;
Prince, RA .
ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (01) :39-44
[6]   Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats [J].
Siefert, HM ;
Kohlsdorfer, C ;
Steinke, W ;
Witt, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :61-67